Procedures Applicable to Commercialization of an Invention Sample Clauses

Procedures Applicable to Commercialization of an Invention. 16.4.1 No Inventor is obliged to engage in commercialization of an Invention. The Inventor is free to publish or use other means to place the Invention in the public domain as an alternative or in addition to using the provisions contained in Article 16.5, subject to any conveyance or arrangement agreed to by the Inventor. 16.4.2 If an Inventor wishes to pursue commercialization, the Inventor shall disclose the Invention and the names of all known Contributors and co-Inventors to the Office of the Vice-Principal (Research) or its delegate, as soon as practicable. Disclosure shall be on the “Invention Disclosure Form” or such other form prescribed by the Office of the Vice-Principal (Research). 16.4.3 An Inventor or Inventors has/have the right to determine whether to engage in commercialization of the Invention as long as such commercialization is consistent with the University’s research policy and contractual constraints that may apply in individual cases. 16.4.4 Upon disclosure by an Inventor under Article 16.4.2 to the Office of the Vice-Principal (Research) or its delegate, the University shall have an exclusive opportunity for ninety
Sample 1Sample 2Sample 3See All (8)
Procedures Applicable to Commercialization of an Invention. 16.4.1 No Inventor is obliged to engage in commercialization of an Invention. The Inventor is free to publish or use other means to place the Invention in the public domain as an alternative or in addition to using the provisions contained in Article 16.5, subject to any conveyance or arrangement agreed to by the Inventor. 16.4.2 If an Inventor wishes to pursue commercialization, he or she shall disclose the Invention and the names of all known Contributors and co-Inventors to the Office of the Vice- Principal (Research) or its delegate, PARTEQ, as soon as practicable. Disclosure shall be on the PARTEQ “Invention Disclosure Form” or such other form prescribed by the Office of the Vice-Principal (Research). 16.4.3 Inventors have the right to determine whether to engage in commercialization of the Invention as long as such commercialization is consistent with the University’s research policy and contractual constraints that may apply in individual cases. 16.4.4 Upon disclosure by an Inventor under Article 16.4.2 to the Office of the Vice-Principal (Research) or its delegate, PARTEQ, PARTEQ shall have an exclusive opportunity for ninety (90) calendar days to make an offer for commercialization acceptable to the Inventor(s). Any disclosure and its contents shall be kept in confidence by the University, and the University shall require PARTEQ to keep any disclosure and its contents in confidence. 16.4.5 The Inventor has no obligation to accept a PARTEQ offer. The consent of all Inventors who have disclosed the Invention in accordance with Article 16.4.2 is required before a PARTEQ offer may be accepted. 16.4.6 PARTEQ may decline to make an offer for commercialization for business reasons.
Sample 1Sample 2Sample 3See All (8)
Procedures Applicable to Commercialization of an Invention. 16.4.1 No Inventor is obliged to engage in commercialization of an Invention. The Inventor is free to publish or use other means to place the intellectual property in the public domain as an alternative to the provisions contained in Article 16.5, subject to any conveyance or arrangement agreed to by the Member. 16.4.2 If an Inventor wishes to pursue commercialization, he or she shall disclose the Invention and the names of all co-Inventors to the Office of the Vice-Principal (Research) as soon as practicable. Disclosure shall be on the PARTEQ “Invention Disclosure Form” or such other form prescribed by the Office of the Vice-Principal (Research). 16.4.3 Upon disclosure of an Invention, the Office of the Vice-Principal (Research) shall investigate with due diligence the extent of involvement of any and all co-Inventors whether or not they are identified on the Invention Disclosure Form. 16.4.4 Inventors have the right to determine whether to engage in commercialization of the Invention as long as such commercialization is consistent with the University’s research policy and contractual constraints that may apply in individual cases.
Sample 1Sample 2Sample 3See All (4)
Procedures Applicable to Commercialization of an Invention. 16.4.1 No Inventor is obliged to engage in commercialization of an Invention. The Inventor is free to publish or use other means to place the Inventionintellectual property in the public domain as an alternative or in addition to using the provisions contained in Article 16.5, subject to any conveyance or arrangement agreed to by the Member Inventor. 16.4.2 If an Inventor wishes to pursue commercialization, he or she shall disclose the Invention and the names of all known Contributors and co-Inventors to the Office of the Vice-Principal (Research) or its delegate, PARTEQ, as soon as practicable. Disclosure shall be on the PARTEQ “Invention Disclosure Form” or such other form prescribed by the Office of the Vice-Principal (Research). 16.4.3 Upon disclosure of an Invention, the Office of the Vice-Principal (Research) shall investigate with due diligence the extent of involvement of any and all co-Inventors whether or not they are identified on the Invention Disclosure Form.
Sample 1

Related to Procedures Applicable to Commercialization of an Invention

  • DEVELOPMENT OR ASSISTANCE IN DEVELOPMENT OF SPECIFICATIONS REQUIREMENTS/ STATEMENTS OF WORK

  • Commercialization Plan At such times as the JGC will deem appropriate, the JGC will direct the Parties to mutually prepare a Worldwide Commercialization Plan, and the JGC will review and approve such initial Worldwide Commercialization Plan. Thereafter, the JGC will have one or the other Party (or both) update the Worldwide Commercialization Plan each calendar year, and the JGC will review and approve any such update or any other amendment to the Worldwide Commercialization Plan. Notwithstanding anything in this CCPS Agreement to the contrary, the Parties acknowledge and agree that (i) Bluebird may decline to perform any Commercialization activity proposed to be conducted by Bluebird in the Worldwide Commercialization Plan (other than Manufacturing of Vectors and associated Payloads), and (ii) the Worldwide Commercialization Plan will not include, and Bluebird will have no obligation to perform, any such Commercialization activity that Bluebird has declined to perform, provided that once Bluebird has agreed to perform a Commercialization activity, it will be obligated to perform, and cannot decline to perform, such activity. In addition, either Party may request at any time that the JGC consider and approve other updates to the Worldwide Commercialization Plan. Further: (a) The JGC will set the required form and contents of the Worldwide Commercialization Plan. The Worldwide Commercialization Plan will reflect a singular marketing and sales approach worldwide, and will specify, among other things, the number of sales reps in the U.S. for each Party, allocation of regions in the U.S. for each Parties’ sales force, creation of marketing materials, planning for conferences, and other marketing activities. CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. (b) Neither Party (itself or by or through any others, including any Affiliates or Sublicensees) will take any material action regarding the Commercialization of Licensed Product unless described in the Worldwide Commercialization Plan or approved by the JGC. (c) All Commercialization of Licensed Product for U.S. Administration will be conducted under the supervision of the JGC and as part of the U.S. Development & Commercialization Program. (d) Celgene will have final decision making authority for all Commercialization activities worldwide, including timing of launch and pricing and the Worldwide Development Plan.

  • Particular Methods of Procurement of Goods and Works International Competitive Bidding. Goods and works shall be procured under contracts awarded on the basis of International Competitive Bidding.

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Indemnification for Marketing Materials In addition to the foregoing indemnification, the Fund and the Investment Adviser also, jointly and severally, agree to indemnify and hold harmless each Underwriter, affiliates, directors, officers, employees and agents of each Underwriter, and each person, if any, who controls any Underwriter within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in Section 6(a), as limited by the proviso set forth therein, with respect to any sales material.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Concession Area, including its abandonment.

  • Marking of Licensed Products To the extent commercially feasible and consistent with prevailing business practices, Company shall xxxx, and shall cause its Affiliates and Sublicensees to xxxx, all Licensed Products that are manufactured or sold under this Agreement with the number of each issued patent under the Patent Rights that applies to such Licensed Product.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.